Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer
Recruiting · NCT05086614 · Interventional (participants receive a specific treatment) · Lead sponsor: Fudan University
View the official record on ClinicalTrials.gov →Interventions studied
Thymosin Alpha1
What this trial is about
For high-risk stage II and stage III colorectal cancer, even after radical resection and postoperative adjuvant chemo/radiotherapy, 30-40% of patients will still have recurrence and metastasis. Thymosin-alpha 1 is believed to improve immunity and may help promote tumor immunity to reduce the incidence of recurrence and metastasis. This study hopes to verify the effecacy and safety of thymosin-alpha 1 for adjuvant treatment of high-risk stage II and stage III colorectal cancer after radical resection.
Who can take part
Age range
18 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 3
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Colorectal cancer receiving radical resection
- Pathologically diagnosed with high-risk stage II or stage III
- Eastern Cooperative Oncology Group performance status of 0-2
- Adequate hepatic, renal, and hematologic function
Exclusion criteria
- Had previously taken any immune-promoting drugs
- Pregnancy or lactation
Where it is running
1 location listed.
- Zhongshan Hospital, Fudan University - Shanghai, Shanghai Municipality, China